Side-by-side comparison of AI visibility scores, market position, and capabilities
Major ambulatory EHR serving 150K providers bootstrapped to scale; Sunoh.ai ambient clinical documentation and revenue cycle management competing with Epic and athenahealth for practices.
eClinicalWorks is one of the largest electronic health record (EHR) and practice management software providers in the United States, serving approximately 150,000 providers across 850,000 care sites with ambulatory EHR, revenue cycle management, patient engagement, and population health tools. Founded in 1999 by Girish Navani and headquartered in Westborough, Massachusetts, eClinicalWorks is privately held and is notable for being a bootstrapped company that has grown to significant scale without venture capital funding, generating substantial annual revenue from its large installed physician base.\n\neClinicalWorks' platform covers the ambulatory (outpatient) clinical workflow: clinical documentation with specialty-specific templates, order entry for labs and imaging, e-prescribing, chronic disease management registries, telehealth (healow TeleVisits), and patient portal. The revenue cycle management capabilities handle insurance claims submission, denial management, and patient billing. Population health tools enable practices and health systems to identify at-risk patient populations and coordinate care across attributed patients.\n\nIn 2025, eClinicalWorks competes with Epic (the dominant health system EHR), athenahealth (cloud-native ambulatory EHR), Oracle Health (Cerner), and Modernizing Medicine for physician practice EHR market share. The company has faced regulatory challenges — in 2017, eClinicalWorks paid $155 million to settle Department of Justice charges related to EHR certification fraud. Despite this, the company retained most of its customer base due to high switching costs inherent in EHR changes. The 2025 strategy focuses on its AI assistant Sunoh.ai (ambient clinical documentation that automatically generates SOAP notes from recorded patient visits), expanding telehealth capabilities, and growing the healow patient engagement platform.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.